Predictive and Diagnostic Value of Tau and Beta-amyloid Markers in the Dementia of Parkinson's Disease

Exclusion Criteria

• •The subject is pregnant or breastfeeding;
• •The subject has a history of drug abuse or alcohol;
• •The subject has developed dementia in the first year of parkinsonism or before than parkinsonism;
• •The subject meets criteria for vascular dementia;
• •The subject has symptoms suggestive of other types of parkinsonism (multi-system atrophy cortico-basal, supra-nuclear palsy progressive degeneration) or degenerative dementia (fronto-temporal dementia);
• •The subject has a moderate or severe renal functional impairment (serum creatinine\> 1.5 mg / dL);
• •The subject has a moderate or severe hepatic impairment (bilirubin\> 2 times the upper limit of normal, transaminases\> 3 times the upper limit of normal);
• •The subject presents structural abnormalities in basal ganglia or cortical level on magnetic resonance imaging or computerized tomography;
• •The subject has participated in a clinical study with an investigational drug product within 30 days prior to screening and / or radiopharmaceutical in a minimum period of 5 radioactive half-lives prior to screening;
• •Occupational exposure to radiation\> 15 milliSievert (mSv) / year
• •The subject has received treatment with non-steroidal anti-inflammatory drugs during the 30-day period before the PET scan
• •The subject has allergy to the investigational product or any of its components;
• •The subject has a clinically active, serious disease with a reduced life expectancy;
• •The subject is claustrophobic / a.
• •The subject has received in the last 364 days a dose of ionizing radiation that coupled with the study dose exceeds 10 mSv